

## Curriculum Vitae Dr Emiliano Fabiani

| PERSONAL DATA       |  |
|---------------------|--|
| Name                | Emiliano Fabiani   |
| Date/place of birth | 10-22-1972. Rome, Italy  |
| Citizenship         | Italian  |
| Work address        | Department of Biomedicine and Prevention,<br>University of Rome "Tor Vergata"<br>Via Montpellier, 1. 00133 Rome, Italy |
| Office phone number | +39 06 72596280  |



| EDUCATION                            |             |   |      |
|--------------------------------------|-------------|---|------|
| Università Cattolica del Sacro Cuore | Rome, Italy | PhD "Technological Applications in Haematology" | 2008 |
| Università Sapienza                  | Rome, Italy | Biology (110/110 cum laude)                     | 2004 |

| RESEARCH EXPERIENCE |  |  |
|---------------------|--|--|
| Mar 2018- Present   | Research grant                                 | Next Generation Sequencing for the study of the mutational landscape of therapy-related Myeloid Neoplasm |
| Feb 2016- Jan 2018  | Research grant                                 | ATRA and ATO versus ATRA and chemotherapy in high risk APL patients                                      |
| Feb 2013- Jan 2016  | University researcher (ART. 24 C.3-A L 240/10) | Genetic and epigenetic profile of therapy-related myeloid neoplasms                                      |
| Nov 2012- Jan 2013  | Research grant                                 | Identification of new targets of susceptibility, prognosis and therapy in <i>de novo</i> and sec-AML     |
| Apr 2011- Mar 2012  | Research grant                                 | Epigenetics of lymphoproliferative disorders   |
| Jan 2009- Dec 2010  | Research grant                                 | Characterization of leukemic stem cell and its relation with healthy hematopoietic stem cell             |

| RESEARCH INTERESTS  |
|---|
| <ul style="list-style-type: none"> <li>• Mutational landscape of <i>de novo</i> and therapy-related MDS and AML</li> <li>• Epigenetic profile of <i>de novo</i> and therapy-related MDS and AML</li> <li>• Impact of single nucleotide polymorphisms (SNPs) in <i>de novo</i> MDS, <i>de novo</i> AML and therapy-related myeloid neoplasm</li> <li>• Predictors of response in intermediate-2/high risk MDS and low blast count AML patients treated with hypomethylating agents</li> <li>• Hypomethylating agents as a bridge for bone marrow transplantation in MDS and AML patients</li> <li>• Predictors of response to iron-chelation agents</li> <li>• Bone marrow microenvironment</li> </ul> |

## PUBLICATIONS

1. GURNARI C, FALCONI G, DE BELLIS E, VOSO MT AND **FABIANI E**. THE ROLE OF FORKHEAD BOX PROTEINS IN ACUTE MYELOID LEUKEMIA. *CANCERS (BASEL)*. 2019 JUN 21;11(6). pii: E865. doi: 10.3390/CANCERS11060865. REVIEW.
2. **FABIANI E**, VALENTINI L, CILLONI D, VOSO MT. COULD HAEMOCHROMATOSIS (HFE) GENE MUTATIONS AFFECT RESPONSE TO IRON CHELATION I MYELODYSPLASTIC SYNDROME? – RESPONSE TO LUCIJANIC AND KUSEC. *BR J HAEMATOL*. 2019 MAY 1. DOI: 10.1111/BJH.15938. [EPUB AHEAD OF PRINT].
3. GURNARI C, LOMBARDI AM, COSI E, BIAGETTI G, BUCCISANO F, FRANCESCHINI L, DI VEROLI A, FALCONI G, **FABIANI E**, CANTONETTI M, NASSO D, LO-COCO F, RANDI ML, VOSO MT. GENETIC ANALYSIS OF ERYTHROCYTOSIS REVEALS POSSIBLE CAUSATIVE AND MODIFIER GENE MUTATIONS. *BR J HAEMATOL*. 2019 APR 23. doi: 10.1111/BJH.15931.
4. **FABIANI E**, CALABRESE C, NISCOLA P, BALLEARI E, MOLteni A, FINELLI C, FALCONI G, FENU S, FIANCHI L, CRISCUOLO M, SALVI F, LAVORGNA S, BUCCISANO F, MAURILLO L, LO COCO F, CILLONI D, VOSO MT. MUTATIONAL PROFILE AND HAEMATOLOGICAL RESPONSE TO IRON CHELATION IN MYELODYSPLASTIC SYNDROMES (MDS). *BR J HAEMATOL*. 2018 NOV 8. doi: 10.1111/BJH.15655. [EPUB AHEAD OF PRINT].
5. FALCONI G, **FABIANI E**, PICIOCCHI A, CRISCUOLO M, FIANCHI L, LINDFORS ROSSI EL, FINELLI C, CERQUI E, OTTONE T, MOLteni A, PARMA M, SANTARONE S, CANDONI A, SICA S, LEONE G, LO-COCO F, VOSO MT. SOMATIC MUTATIONS AS MARKERS OF OUTCOME AFTER AZACITIDINE AND ALLOGENEIC STEM CELL TRANSPLANTATION IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES. *LEUKEMIA*. 2018 OCT 5. doi: 10.1038/s41375-018-0284-9.
6. FIANCHI L, CRISCUOLO M, **FABIANI E**, FALCONI G, MARAGLINO AME, VOSO MT, PAGANO L. THERAPY-RELATED MYELOID NEOPLASMS: CLINICAL PERSPECTIVES. *ONCO TARGETS THER*. 2018 SEP 17;11:5909-5915. doi: 10.2147/OTT.S101333. eCOLLECTION 2018. REVIEW.
7. GURNARI C, PANETTA P, **FABIANI E**, NARDONE AM, POSTORIVO D, FALCONI G, FRANCESCHINI L, RIZZO M, RAPISARDA VM, DE BELLIS E, LO-COCO F, VOSO MT. IDENTIFICATION OF I(X)(P10) AS THE SOLE MOLECULAR ABNORMALITY IN ATYPICAL CHRONIC MYELOID LEUKEMIA EVOLVED INTO ACUTE MYELOID LEUKEMIA. *MOL CLIN ONCOL*. 2018 MAR;8(3):463-465. doi: 10.3892/MCO.2017.1543. EPUB 2017 DEC 29.
8. OTTONE T, ALFONSO V, IACCARINO L, HASAN SK, MANCINI M, DIVONA M, LAVORGNA S, CICCONE L, PANETTA P, MAURILLO L, DEL PRINCIPE MI, IRNO CONSALVO M, FRANCESCHINI L, FRANCESCA ANGELINI D, BATTISTINI L, GUERRERA G, DE BARDI M, **FABIANI E**, FALCONI G, ARCESE W, AMADORI S, BUCCISANO F, VENDITTI A, VOSO MT, LO-COCO F. LONGITUDINAL DETECTION OF DNMT3AR882H TRANSCRIPTS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. *AM J HEMATOL*. 2018 FEB 8. doi: 10.1002/AJH.25061. [EPUB AHEAD OF PRINT].
9. VISANI G, LOSCOCO F, RUZZO A, GALIMBERTI S, GRAZIANO F, VOSO MT, GIACOMINI E, FINELLI C, CIABATTI E, **FABIANI E**, BARULLI S, VOLPE A, MAGRO D, PICCALUGA P, FULIGNI F, VIGNETTI M, FAZI P, PICIOCCHI A, GABUCCI E, ROCCHI M, MAGNANI M, ISIDORI A. MTHFR, TS AND XRCC1 GENETIC VARIANTS MAY AFFECT SURVIVAL IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH SUPPORTIVE CARE OR AZACITIDINE. *PHARMACOGENOMICS J*. 2017 DEC 5. doi: 10.1038/TPJ.2017.48. [EPUB AHEAD OF PRINT].
10. **EMILIANO FABIANI**, GIULIA FALCONI, NELIDA INES NOGUERA, ERNESTINA SAULLE, LAURA CICCONE, MARIADOMENICA DIVONA, CRISTINA BANELLA, ALESSANDRA PICARDI, ANNA MARIA CERIO, LETIZIA BOE, MASSIMO SANCHEZ, ELVIRA PELOSI, UGO TESTA, FRANCESCO LO-COCO AND MARIA TERESA VOSO. THE FORKHEAD BOX C1 (FOXC1) TRANSCRIPTION FACTOR IS DOWNREGULATED IN ACUTE PROMYELOCYTIC LEUKEMIA. *ONCOTARGET*. 2017 SEP 20;8(48):84074-84085. doi: 10.18632/ONCOTARGET.21101.
11. **FABIANI E**, FALCONI G, FIANCHI L, CRISCUOLO M, OTTONE T, CICCONE L, HOHAUS S, SICA S, POSTORINO M, NERI A, LIONETTI M, LEONE G, LO-COCO F, TERESA VOSO M. CLONAL EVOLUTION IN THERAPY-RELATED NEOPLASMS. *ONCOTARGET*. 2017 FEB 14;8(7):12031-12040. doi: 10.18632/ONCOTARGET.14509.
12. GARZA E, DEL POETA G, MARTÍNEZ-LOSADA C, CATALANO G, BORGIA L, PIREDDA ML, **FABIANI E**, GATTEI V, LO-COCO F, NOGUERA NI. A CASE OF SRSF2 MUTATION IN CHRONIC LYMPHOCYTIC LEUKEMIA. *LEUK RES REP*. 2016 JUN 23;6:11-4. doi: 10.1016/J.LRR.2016.03.001. eCOLLECTION 2016.
13. GIULIA FALCONI, **EMILIANO FABIANI**, LUANA FIANCHI, MARIANNA CRISCUOLO, CHIARA SPERTILLI RAFFAELLI, SILVIA BELLESI, STEFAN HOHAUS, MARIA TERESA VOSO, FRANCESCO D'ALÒ, GIUSEPPE LEONE. IMPAIRMENT OF PI3K-AKT AND WNT-B CATENIN PATHWAYS IN BONE MARROW MESENCHYMAL STEM CELLS ISOLATED FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES. *EXP HEMATOL*. 2016 JAN;44(1):75-83.e1-4. doi: 10.1016/J.EXPHEM.2015.10.005. EPUB 2015 OCT 28.

14. VOSO MT, **FABIANI E**, ZANG Z, FIANCHI L, FALCONI G, PADELLA A, MARTINI M, LI ZHANG S, SANTANGELO R, LAROCCA LM, CRISCUOLO M, LA BROCCA A, CUTCUTACHE I, ROZEN S, SIMONETTI G, MANFRINI M, MARTINELLI G, HOHAUS S, LEONE G, TAN P, TENEN DG. FANCONI ANEMIA GENE VARIANTS IN THERAPY-RELATED MYELOID NEOPLASMS. *BLOOD CANCER J*. 2015 JUL 3;5:E323. doi: 10.1038/bcj.2015.44.
15. TEOFILI L, MARTINI M, NUZZOLO ER, CAPODIMONTI S, IACHININOTO MG, COCOMAZZI A, **FABIANI E**, VOSO MT, LAROCCA LM. ENDOTHELIAL PROGENITOR CELL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMES: POSSIBLE CONTRIBUTION OF A DEFECTIVE VASCULAR NICHE TO MYELODYSPLASIA. *NEOPLASIA*. 2015 MAY;17(5):401-9. doi: 10.1016/j.neo.2015.04.001.
16. FIANCHI L, PAGANO L, PICIOCCHI A, CANDONI A, GAIDANO G, BRECCIA M, CRISCUOLO M, SPECCHIA G, MARIA POGLIANI E, MAURILLO L, ALOE-SPIRITI MA, MECUCCI C, NISCOLA P, ROSSETTI E, MANSUETO G, RONDONI M, FOZZA C, INVERNIZZI R, SPADEA A, FENU S, BUDA G, GOBBI M, **FABIANI E**, SICA S, HOHAUS S, LEONE G, VOSO MT. CHARACTERISTICS AND OUTCOME OF THERAPY-RELATED MYELOID NEOPLASMS: REPORT FROM THE ITALIAN NETWORK ON SECONDARY LEUKEMIAS. *AM J HEMATOL*. 2015 MAY;90(5):E80-5. doi: 10.1002/ajh.23966. Epub 2015 MAR 3.
17. GARZA E, **FABIANI E**, NOGUERA N, PANETTA P, PIREDDA ML, BORGIA L, MAURILLO L, CATALANO G, VOSO MT, LO-COCO F. DEVELOPMENT OF A HIGH-RESOLUTION MELTING CURVE ANALYSIS SCREENING TEST FOR SRSF2 SPLICING FACTOR GENE MUTATIONS IN MYELODYSPLASTIC SYNDROMES. *J MOL DIAGN*. 2015 JAN;17(1):85-9. doi: 10.1016/j.jmoldx.2014.08.002.
18. MUSTO P, SIMEON V, GUARIGLIA R, BIANCHINO G, GRIECO V, NOZZA F, LA ROCCA F, MARZIANO G, LALINGA AV, **FABIANI E**, VOSO MT, SCARAVAGLIO P, MECUCCI C, D'ARENA G. MYELODYSPLASTIC DISORDERS CARRYING BOTH ISOLATED DEL(5Q) AND JAK2(V617F) MUTATION: CONCISE REVIEW, WITH FOCUS ON LENALIDOMIDE THERAPY. *ONCO TARGETS THER*. 2014 JUN 13;7:1043-50. doi: 10.2147/OTT.S59628.
19. **FABIANI E**, FALCONI G, FIANCHI L, CRISCUOLO M, LEONE G, VOSO MT. SETBP1 MUTATIONS IN 106 PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASMS. *HAEMATOLOGICA*. 2014 SEP;99(9):E152-3. doi: 10.3324/haematol.2014.108159.
20. **FABIANI E**, FALCONI G, FIANCHI L, GUIDI F, BELLESI S, VOSO MT, LEONE G, D'ALÒ F. MUTATIONAL ANALYSIS OF BONE MARROW MESENCHYMAL STROMAL CELLS IN MYELOID MALIGNANCIES. *EXP HEMATOL*. 2014 SEP;42(9):731-3. doi: 10.1016/j.exphem.2014.04.011.
21. VOSO MT, SANTINI V, **FABIANI E**, FIANCHI L, CRISCUOLO M, FALCONI G, GUIDI F, HOHAUS S, LEONE G. WHY METHYLATION IS NOT A MARKER PREDICTIVE OF RESPONSE TO HYPOMETHYLATING AGENTS. *HAEMATOLOGICA*. 2014 APR;99(4):613-9. doi: 10.3324/haematol.
22. CRISCUOLO M, CHIUSOLO P, GIAMMARCO S, GIACHELIA M, FIANCHI L, **FABIANI E**, FALCONI G, HOHAUS S, SICA S, LEONE G, VOSO MT. METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISMS IN MYELODYSPLASTIC SYNDROMES AND THERAPY-RELATED MYELOID NEOPLASMS. *LEUK LYMPHOMA*. 2014 DEC;55(12):2942-4. doi: 10.3109/10428194.2014.903475.
23. **FABIANI E**, FIANCHI L, FALCONI G, BONCOMPAGNI R, CRISCUOLO M, GUIDI F, LA BROCCA A, HOHAUS S, LEONE G, VOSO MT. THE BCL2L10 LEU21ARG VARIANT AND RISK OF THERAPY-RELATED MYELOID NEOPLASMS AND DE NOVO MYELODYSPLASTIC SYNDROMES. *LEUK LYMPHOMA*. 2014 JUL;55(7):1538-43. doi: 10.3109/10428194.2013.845885.
24. BARBETTI V, GOZZINI A, CHELONI G, MARZI I, **FABIANI E**, SANTINI V, DELLO SBARBA P, ROVIDA E. TIME- AND RESIDUE-SPECIFIC DIFFERENCES IN HISTONE ACETYLATION INDUCED BY VPA AND SAHA IN AML1/ETO-POSITIVE LEUKEMIA CELLS. *EPIGENETICS*. 2013 FEB;8(2):210-9. doi: 10.4161/epi.23538. Epub 2013 JAN 15.
25. VOSO MT, **FABIANI E**, FIANCHI L, FALCONI G, CRISCUOLO M, SANTANGELO R, CHIUSOLO P, BETTI S, D'ALO' F, HOHAUS S, DE STEFANO V, LEONE G. MUTATIONS OF EPIGENETIC REGULATORS AND OF THE SPLICEOSOME MACHINERY IN THERAPY-RELATED MYELOID NEOPLASMS AND IN ACUTE LEUKEMIAS EVOLVED FROM CHRONIC MYELOPROLIFERATIVE DISEASES. *LEUKEMIA*. 2013 APR;27(4):982-5.
26. D'ALÒ F, FIANCHI L, **FABIANI E**, CRISCUOLO M, GRECO M, GUIDI F, PAGANO L, LEONE G, VOSO MT. SIMILARITIES AND DIFFERENCES BETWEEN THERAPY-RELATED AND ELDERLY ACUTE MYELOID LEUKEMIA. *MEDITERR J HEMATOL INFECT DIS*. 2011;3(1):E2011052. Epub 2011 NOV 28.
27. VOSO MT, **FABIANI E**, PICIOCCHI A, MATTEUCCI C, BRANDIMARTE L, FINELLI C, POGLIANI E, ANGIUCCI E, FIORITONI G, MUSTO P, GRECO M, CRISCUOLO M, FIANCHI L, VIGNETTI M, SANTINI V, HOHAUS S, MECUCCI C, LEONE G. ROLE OF BCL2L10 METHYLATION AND TET2 MUTATIONS IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACYTIDINE. *LEUKEMIA*. 2011 DEC;25(12):1910-3. doi: 10.1038/leu.2011.170. Epub 2011 JUL 15.

28. GRECO M, CRISCUOLO M, FIANCHI L, **FABIANI E**, PAGANO L, VOSO M. 5-AZACYTIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: CASE REPORT AND REVIEW OF LITERATURE. *MEDITERR J HEMATOL INFECT DIS*. 2011;3(1):E2011011. EPUB 2011 MAR 15.
29. **FABIANI E**, LEONE G, GIACHELIA M, D'ALO' F, GRECO M, CRISCUOLO M, GUIDI F, RUTELLA S, HOHAUS S, TERESA VOSO M. ANALYSIS OF GENOME-WIDE METHYLATION AND GENE EXPRESSION INDUCED BY 5-AZA-2'-DEOXYCYTIDINE IDENTIFIES BCL2L10 AS A FREQUENT METHYLATION TARGET IN ACUTE MYELOID LEUKEMIA. *LEUK LYMPHOMA*. 2010 DEC;51(12):2275-84. EPUB 2010 NOV 15.
30. GIACHELIA M, D'ALÒ F, **FABIANI E**, SAULNIER N, DI RUSCIO A, GUIDI F, HOHAUS S, VOSO MT, LEONE G. GENE EXPRESSION PROFILING OF MYELODYSPLASTIC CD34+ HEMATOPOIETIC STEM CELLS TREATED IN VITRO WITH DECITABINE. *LEUK RES*. 2010 SEP 22. [EPUB AHEAD OF PRINT].
31. GRECO M, D'ALÒ F, SCARDOCCI A, CRISCUOLO M, **FABIANI E**, GUIDI F, DI RUSCIO A, MIGLIARA G, PAGANO L, FIANCHI L, CHIUSOLO P, HOHAUS S, LEONE G, VOSO MT. PROMOTER METHYLATION OF DAPK1, E-CADHERIN AND THROMBOSPONDIN-1 IN DE NOVO AND THERAPY-RELATED MYELOID NEOPLASMS. *BLOOD CELLS MOL DIS*. 2010 OCT 15;45(3):181-5. EPUB 2010 JUL 24.
32. VOSO MT, D'ALÒ F, GRECO M, **FABIANI E**, CRISCUOLO M, MIGLIARA G, PAGANO L, FIANCHI L, GUIDI F, HOHAUS S, LEONE G. EPIGENETIC CHANGES IN THERAPY-RELATED MDS/AML. *CHEM BIOL INTERACT*. 2010 MAR 19;184(1-2):46-9. EPUB 2009 OCT 27.
33. VOSO MT, SANTINI V, FINELLI C, MUSTO P, POGLIANI E, ANGELUCCI E, FIORITONI G, ALIMENA G, MAURILLO L, CORTELEZZI A, BUCCISANO F, GOBBI M, BORIN L, DI TUCCI A, ZINI G, PETTI MC, MARTINELLI G, **FABIANI E**, FAZI P, VIGNETTI M, PICIOCCHI A, LISO V, AMADORI S, LEONE G. VALPROIC ACID AT THERAPEUTIC PLASMA LEVELS MAY INCREASE 5-AZACYTIDINE EFFICACY IN HIGHER RISK MYELODYSPLASTIC SYNDROMES. *CLIN CANCER RES*. 2009 AUG 1;15(15):5002-7. EPUB 2009 JUL 28.
34. **FABIANI E.**, D'ALÒ F., SCARDOCCI A., ET AL. POLYMORPHISMS OF DETOXIFICATION AND DNA REPAIR ENZYMES IN MYELODYSPLASTIC SYNDROMES. *LEUKEMIA RESEARCH* 33 (2009) 1068–1071.
35. VOSO M. T, HOHAUS S., GUIDI F., **FABIANI E.**, ET AL. PROGNOSTIC ROLE OF GLUTATHIONE S-TRANSFERASE (GST) POLYMORPHISMS IN ACUTE MYELOID LEUKEMIA. *LEUKEMIA* 22, 1685-91, 2008.
36. FRANCESCO D'ALÒ, ANNALISA DI RUSCIO, FRANCESCO GUIDI, **EMILIANO FABIANI**, MARIANGELA GRECO, CARLO RUMI, STEFAN HOHAUS, MARIA TERESA VOSO, GIUSEPPE LEONE. PU.1 AND CEBPA EXPRESSION IN ACUTE MYELOID LEUCEMIA. *LEUKEMIA RESEARCH* 32, 1448-53, 2008.
37. MARIA TERESA VOSO, **EMILIANO FABIANI**, FRANCESCO D'ALO', FRANCESCO GUIDI, ANNALISA DI RUSCIO, SIMONA SICA, LIVIO PAGANO, STEFAN HOHAUS, AND GIUSEPPE LEONE. INCREASED RISK OF ACUTE MYELOID LEUKEMIA DUE TO POLYMORPHISMS IN DETOXIFICATION AND DNA REPAIR ENZYMES. *ANN. ONCOL*. 2007 SEP;18(9):1523-1528.
38. SCARDOCCI A, GUIDI F, D'ALO F, GUMIERO D, **FABIANI E**, DIRUSCIO A, MARTINI M, LAROCCA LM, ZOLLINO M, HOHAUS S, LEONE G, VOSO MT. REDUCED BRCA1 EXPRESSION DUE TO PROMOTER HYPERMETHYLATION IN THERAPY-RELATED ACUTE MYELOID LEUKAEMIA. *BR J CANCER*. 2006 OCT 23;95(8):1108-13.
39. **E. FABIANI**, R.T. PILLICH, G. SCARSELLA E G. RISULEO. LA TRASCRIZIONE DI PDX-1 IN CELLULE TRANSFETTATE NON È DI PER SE SUFFICIENTE PER LA ESPRESSIONE DEL GENE DELL'INSULINA. *BIOLOGI ITALIANI*. NOVEMBRE 2004, 33-36.

#### SCIENTIFIC BOOKS:

- **EMILIANO FABIANI**, FRANCESCO D'ALÒ, GIUSEPPE LEONE AND MARIA TERESA VOSO. "MYELODYSPLASTIC STEM CELLS: GENE EXPRESSION PROFILING". *STEM CELLS AND CANCER STEM CELLS, VOLUME 8, CHAPTER 6, SPRINGER SCIENCE-BUSINESS MEDIA DORDRECHT, 2012.*

## TEACHINGS

- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2018/2019. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 2°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2018/2019. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 3°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2017/2018. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 2°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2017/2018. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 3°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2016/2017. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 2°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2016/2017. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 3°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- TEACHING AND TUTORING ACTIVITIES AT THE FACULTY OF MEDICINE AND SURGERY, UNIVERSITY OF ROME TOR VERGATA, FOR STUDENTS ENROLLED IN THE DEGREE COURSE IN MEDICAL BIOTECHNOLOGY, YEAR 2016-PRESENT.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2015/2016. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 2°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2015/2016. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 3°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2014/2015. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 2°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2014/2015. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 3°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- MEMBER OF THE COUNCIL OF PROFESSORS OF THE PH.D COURSE IN “TECHNOLOGICAL APPLICATIONS IN ONCOHEMATOLOGY” FROM 2012-2013 TO 2014-2015, UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- POST-GRADUATE SPECIALIZATION IN HEMATOLOGY – A.A. 2013/2014. AREA DI LABORATORIO E DIAGNOSTICA, YEAR OF STUDY 1°. UNIVERSITÀ CATTOLICA DEL SACRO CUORE, ROMA, ITALY.
- UNIVERSITY MASTER 2° DEGREE IN HEMATOLOGY, “ACUTE MYELOID LEUKEMIA”, 15-17 LUGLIO 2013. SAPIENZA, ROMA, FACOLTA' DI FARMACIA E MEDICINA, DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA, SEZIONE DI EMATOLOGIA, DIRETTORE PROF. ROBERTO FOÀ. LESSON TITLE “IL POLIMORFISMO GENICO E LE ALTERAZIONI EPIGENETICHE NELLA PATOGENESI DI LAM E SMD”. JULY 17, 2013.

## EDITORIAL REVIEW BOARD MEMBER

- JOURNAL OF HEMATOLOGICAL MALIGNANCIES (JHM), INTERNATIONAL PEER-REVIEWED AND OPEN ACCESS JOURNAL FOR PRACTICING HEMATOLOGIST
- JENPUB HEMATOLOGY AND BLOOD DISORDERS (JHBD), OPEN ACCESS, MULTIDISCIPLINARY, COMPREHENSIVE, PEER REVIEWED JOURNAL DEDICATED TO HEMATOLOGY AND BLOOD DISORDERS